The prion protein in human neurodegenerative disorders

被引:28
|
作者
Kovacs, GG
Zerbi, P
Voigtländer, T
Strohschneider, M
Trabattoni, G
Hainfellner, JA
Budka, H
机构
[1] Univ Vienna, Inst Neurol, A-1097 Vienna, Austria
[2] Austrian Reference Ctr Human Prion Dis, AKH 4J, A-1097 Vienna, Austria
[3] L Sacco Univ Milan, Dept Clin Sci, Pathol Unit, Milan, Italy
基金
奥地利科学基金会;
关键词
alpha-synuclein; beta-amyloid; cellular inclusion; neurodegeneration; prion protein; tau;
D O I
10.1016/S0304-3940(02)00668-7
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
We evaluate cellular prion protein (PrPc) immunoreactivity (IR) in Alzheimer's, Parkinson's, diffuse Lewy body, and motor neuron diseases (MND), progressive supranuclear palsy, and multiple system atrophy. We use immunohistochemistry for PrP, including five monoclonal antibodies against different epitopes and three different pretreatments, alpha-synuclein, phosphorylated tau, beta-amyloid, and ubiquitin. Disease-specific inclusions are devoid of PrPc IR. Using double immunofluorescence and confocal laser microscopy we observe focal overlapping of PrPc with tau and with alpha-synuclein in early, but not in fully developed inclusions. However, PrPc IR neurons may contain abnormal tau or alpha-synuclein aggregates. Additionally, we observe a loss of PrPc IR in anterior horn neurons in MIND. Our results suggest that expression of PrPc reflects a general response to cellular stress rather than specific co-operation in aggregation of other proteins. (C) 2002 Published by Elsevier Science Ireland Ltd.
引用
收藏
页码:269 / 272
页数:4
相关论文
共 50 条
  • [31] Imaging of human inflammatory neurodegenerative disorders
    Schmierer, K.
    IMMUNOLOGY, 2010, 131 : 5 - 5
  • [32] Protein misfolding and disease: the case of prion disorders
    Hetz, C
    Soto, C
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2003, 60 (01) : 133 - 143
  • [33] Protein misfolding and disease: the case of prion disorders
    C. Hetz
    C. Soto
    Cellular and Molecular Life Sciences CMLS, 2003, 60 : 133 - 143
  • [34] ALZHEIMER-DISEASE AND THE PRION DISORDERS AMYLOID BETA-PROTEIN AND PRION PROTEIN AMYLOIDOSES
    PRICE, DL
    BORCHELT, DR
    SISODIA, SS
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (14) : 6381 - 6384
  • [35] Neurodegenerative illness in transgenic mice expressing a transmembrane form of the prion protein
    Stewart, RS
    Piccardo, P
    Ghetti, B
    Harris, DA
    JOURNAL OF NEUROSCIENCE, 2005, 25 (13): : 3469 - 3477
  • [36] A roadmap for investigating the role of the prion protein in depression associated with neurodegenerative disease
    Beckman, Danielle
    Linden, Rafael
    PRION, 2016, 10 (02) : 131 - 142
  • [37] Novel prion protein insert mutation associated with prolonged neurodegenerative illness
    Lewis, V
    Collins, S
    Hill, AF
    Boyd, A
    McLean, CA
    Smith, M
    Masters, CL
    NEUROLOGY, 2003, 60 (10) : 1620 - 1624
  • [38] Plasma total prion protein as a potential biomarker for neurodegenerative dementia: diagnostic accuracy in the spectrum of prion diseases
    Llorens, F.
    Villar-Pique, A.
    Schmitz, M.
    Diaz-Lucena, D.
    Wohlhage, M.
    Hermann, P.
    Goebel, S.
    Schmidt, I
    Glatzel, M.
    Hauw, J-J
    Sikorska, B.
    Liberski, P. P.
    Riggert, J.
    Ferrer, I
    Zerr, I
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2020, 46 (03) : 240 - 254
  • [39] Protein misfolding and medicinal strategies in neurodegenerative disorders
    Mehboudi, Leila
    Zahedirad, Mehrshad
    Vadiei, Parisa
    MEDICINA BALEAR, 2022, 37 (04): : 166 - 170
  • [40] Protein precipitation: a common etiology in neurodegenerative disorders?
    Kakizuka, A
    TRENDS IN GENETICS, 1998, 14 (10) : 396 - 402